Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 29, 2018 - Acadia Pharmaceuticals announced the FDA approval of Nuplazid (pimavanserin) 34 mg capsules for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Return to publications